JP5082033B2 - Lxrのモジュレーター - Google Patents
Lxrのモジュレーター Download PDFInfo
- Publication number
- JP5082033B2 JP5082033B2 JP2003559988A JP2003559988A JP5082033B2 JP 5082033 B2 JP5082033 B2 JP 5082033B2 JP 2003559988 A JP2003559988 A JP 2003559988A JP 2003559988 A JP2003559988 A JP 2003559988A JP 5082033 B2 JP5082033 B2 JP 5082033B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- phenyl
- methyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34270701P | 2001-12-21 | 2001-12-21 | |
US60/342,707 | 2001-12-21 | ||
PCT/US2002/041306 WO2003059884A1 (en) | 2001-12-21 | 2002-12-20 | Modulators of lxr |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010212875A Division JP2010280732A (ja) | 2001-12-21 | 2010-09-22 | Lxrのモジュレーター |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005536450A JP2005536450A (ja) | 2005-12-02 |
JP2005536450A5 JP2005536450A5 (US07998986-20110816-C00495.png) | 2006-05-18 |
JP5082033B2 true JP5082033B2 (ja) | 2012-11-28 |
Family
ID=23342938
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003559988A Expired - Lifetime JP5082033B2 (ja) | 2001-12-21 | 2002-12-20 | Lxrのモジュレーター |
JP2010212875A Withdrawn JP2010280732A (ja) | 2001-12-21 | 2010-09-22 | Lxrのモジュレーター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010212875A Withdrawn JP2010280732A (ja) | 2001-12-21 | 2010-09-22 | Lxrのモジュレーター |
Country Status (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010280732A (ja) * | 2001-12-21 | 2010-12-16 | X-Ceptor Therapeutics Inc | Lxrのモジュレーター |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696473B2 (en) | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
EP1511483A4 (en) * | 2002-03-27 | 2009-03-18 | Smithkline Beecham Corp | PROCESSING METHODS USING LXR MODULATORS |
EP1646615B1 (en) * | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
WO2005019264A2 (en) * | 2003-08-18 | 2005-03-03 | Wyeth | Human lxr alpha variants |
CA2548374C (en) | 2003-12-23 | 2014-05-27 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
WO2005100396A1 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoid x receptor alpha (rxra) |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006046593A1 (ja) | 2004-10-27 | 2006-05-04 | Daiichi Sankyo Company, Limited | 2以上の置換基を有するベンゼン化合物 |
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
US8158652B2 (en) * | 2004-12-01 | 2012-04-17 | Msd K.K. | Substituted pyridone derivative |
WO2006077012A2 (en) * | 2005-01-18 | 2006-07-27 | Genfit S.A. | USE OF LXR LIGANDS FOR THE MODULATION OF DENDRITIC CELLS (DCs) |
WO2006136821A1 (en) | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8541461B2 (en) | 2005-06-23 | 2013-09-24 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
US7790745B2 (en) * | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
KR20150038395A (ko) | 2006-04-04 | 2015-04-08 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
FR2903105A1 (fr) * | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
WO2008036238A2 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr modulators for the prevention and treatment of skin aging |
US20090012053A1 (en) * | 2006-09-19 | 2009-01-08 | Wyeth | Use of LXR agonists for the treatment of osteoarthritis |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP2144902B1 (en) * | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
JP2010526146A (ja) * | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | [6,5]−二環式gpr119gタンパク質結合受容体アゴニスト |
JPWO2008149965A1 (ja) | 2007-06-07 | 2010-08-26 | アステラス製薬株式会社 | ピリドン化合物 |
ES2371515T3 (es) * | 2007-07-17 | 2012-01-04 | Bristol-Myers Squibb Company | Agonistas del receptor grp119 acoplado a proteína g. piridona. |
MX2010002266A (es) * | 2007-08-30 | 2010-03-25 | Takeda Pharmaceutical | Derivados de pirazol sustituidos. |
SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
EA019085B1 (ru) | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
US20090209601A1 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteoarthritis |
NZ587719A (en) | 2008-02-26 | 2012-04-27 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
CN102066326A (zh) | 2008-06-17 | 2011-05-18 | 安斯泰来制药株式会社 | 吡啶酮化合物 |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
BRPI0918055A2 (pt) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato. |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
EP2356109B1 (en) * | 2008-10-10 | 2016-12-07 | VM Discovery, Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
JP5819195B2 (ja) | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
ME01573B (me) | 2009-05-12 | 2014-09-20 | Addex Pharma Sa | DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
EP2471791B1 (en) | 2009-08-26 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
US8486965B2 (en) | 2009-08-26 | 2013-07-16 | Takeda Pharmaceutical Company Limited | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer |
WO2011024871A1 (ja) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
EP2471790B1 (en) | 2009-08-26 | 2015-03-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
JP2013523822A (ja) | 2010-04-08 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | Gpr119修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体 |
EP2566862B1 (en) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
WO2012033353A2 (ko) | 2010-09-07 | 2012-03-15 | 서울대학교 산학협력단 | 세스터터핀 화합물 및 이들 물질의 용도 |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
SG10201600179RA (en) | 2011-01-10 | 2016-02-26 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
EP2678018A4 (en) | 2011-02-23 | 2015-09-30 | Intellikine Llc | COMBINATION OF CHINESE HEMMER AND USES THEREOF |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
AU2012284091B2 (en) | 2011-07-19 | 2015-11-12 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
CN105188380B (zh) | 2013-03-15 | 2017-08-15 | 百时美施贵宝公司 | Lxr调节剂 |
JP6442475B2 (ja) | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
WO2014207601A1 (en) | 2013-06-27 | 2014-12-31 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
SI3431106T1 (sl) | 2014-01-21 | 2021-03-31 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2016057454A1 (en) | 2014-10-06 | 2016-04-14 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
WO2017123568A2 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2018016227A (es) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
JP7072557B2 (ja) | 2016-07-22 | 2022-05-20 | ブリストル-マイヤーズ スクイブ カンパニー | グルコキナーゼ活性化剤およびその使用方法 |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
CN113302206A (zh) | 2018-11-26 | 2021-08-24 | 戴纳立制药公司 | 治疗脂质代谢失调的方法 |
CA3161274A1 (en) | 2019-12-13 | 2021-06-17 | Stephen Wald | Metal salts and uses thereof |
Family Cites Families (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US147493A (en) * | 1874-02-17 | Improvement in curtain-cord holders | ||
US137805A (en) * | 1873-04-15 | Improvement in broom-corn dusters | ||
US226727A (en) * | 1880-04-20 | Car-coupling | ||
US103705A (en) * | 1870-05-31 | Improvement in scissors-sharpener | ||
US54759A (en) * | 1866-05-15 | Improvement in pantographic machines | ||
US2556A (en) * | 1842-04-16 | Stove | ||
US624583A (en) * | 1899-05-09 | Paper box | ||
US294995A (en) * | 1884-03-11 | Ments | ||
US73277A (en) * | 1868-01-14 | Improvement in gates | ||
US17334A (en) * | 1857-05-19 | Machinery for dressing sewing-thread | ||
US339105A (en) * | 1886-03-30 | John l | ||
US160818A (en) * | 1875-03-16 | Improvement in bucket-ears | ||
US176064A (en) * | 1876-04-11 | Improvement in screw-cutting machines | ||
US236581A (en) * | 1881-01-11 | haworth | ||
US557843A (en) * | 1896-04-07 | Octave-coupler for organs | ||
US72073A (en) | 1867-12-10 | Improved boot and shoe-heels | ||
US51813A (en) * | 1866-01-02 | Improvement in the manufacture of paper-pulp | ||
US122964A (en) * | 1872-01-23 | 1872-01-23 | Improvement in watches | |
US755934A (en) * | 1904-02-17 | 1904-03-29 | George M Potter | Detonator. |
US1226832A (en) * | 1916-08-09 | 1917-05-22 | Fred M Webber | Pneumatic pitman-balance for swing-jaw rock and ore crushers. |
US1261371A (en) * | 1917-05-02 | 1918-04-02 | John Ellingsen | Window construction. |
US5625041A (en) | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
US2077412A (en) * | 1930-06-04 | 1937-04-20 | Eugene J Lorand | Process for the preparation of a molded cellulose foam from viscose and product thereof |
US2345058A (en) * | 1939-11-25 | 1944-03-28 | Aetna Standard Eng Co | Method of galvanizing |
US2824341A (en) * | 1953-11-25 | 1958-02-25 | Harold B Neal | Awning |
DE1189994B (de) * | 1957-11-20 | 1965-04-01 | Hoechst Ag | Verfahren zur Herstellung von 1-Aminopyridon-(6)-derivaten |
CH477475A (de) * | 1966-07-25 | 1969-08-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Derivaten der 6-Amino-penicillansäure |
US3576814A (en) * | 1970-01-30 | 1971-04-27 | Rohm & Haas | N-aryl pyrid-2-ones |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
US4159202A (en) | 1973-12-20 | 1979-06-26 | Hoechst Aktiengesellschaft | Photopolymer having 2-pyridone side group |
US3954734A (en) | 1974-01-21 | 1976-05-04 | Parke, Davis & Company | Novel antibacterial amide compounds and process means for producing the same |
US4038065A (en) | 1974-10-11 | 1977-07-26 | Rohm And Haas Company | 1-alkylpyrid-2-one |
US4028084A (en) | 1974-10-11 | 1977-06-07 | Rohm And Haas Company | Derivatives of 3-carboxy pyrid-2-ones |
US3951982A (en) | 1974-11-21 | 1976-04-20 | Parke, Davis & Company | Trialkylsilyl esters of 6(substituted amino)phenyl-1,-dihydro-2-oxonicotinic acid, methods for their production and conversion to the corresponding acid chlorides |
US4053470A (en) | 1974-12-23 | 1977-10-11 | Parke, Davis & Company | Substituted-1,2-dihydro-2-oxonicotinyl-cephalosporins |
IT1039699B (it) | 1975-07-03 | 1979-12-10 | Prephar | Composizione spermicida a base di derivati benzisotiazolici |
DE2637477A1 (de) * | 1976-08-20 | 1978-02-23 | Hoechst Ag | Dihydro-oxo-nicotinsaeuren und verfahren zu ihrer herstellung |
JPS5350179A (en) * | 1976-10-15 | 1978-05-08 | Rikagaku Kenkyusho | Novel 2-pyridone compounds and their preparation |
US4101661A (en) | 1977-06-03 | 1978-07-18 | Warner-Lambert | Novel antibacterial amide compounds and process means for producing the same |
CA1115278A (en) | 1979-01-10 | 1981-12-29 | Benjamin J. Pierce | Anti-inflammatory 4-pyridones and their preparation |
GB2045236A (en) | 1979-03-26 | 1980-10-29 | Hoechst Uk Ltd | Oxapenem derivatives |
FR2456713A1 (fr) * | 1979-05-17 | 1980-12-12 | Emballage Ste Gle Pour | Melanges vitrifiables |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
JPS5726653A (en) | 1980-05-09 | 1982-02-12 | Ciba Geigy Ag | Substituted phenyl ether |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4309552A (en) * | 1980-08-07 | 1982-01-05 | A. H. Robins Company, Inc. | Synthesis of 4-nitro-1,2-hydrocarbyl pyrazolidines and process for preparation thereof |
ATE21105T1 (de) | 1980-11-06 | 1986-08-15 | Hoechst Uk Ltd | 7-oxo-4-thia-1-aza(3.2.0)heptan- und 7-oxo-4-thia-1-aza-(3.2.0)hept-2-en-derivate. |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4585894A (en) | 1983-10-19 | 1986-04-29 | Eli Lilly And Company | Process for producing 9-carbamoyl fluorene derivatives |
FI844067L (fi) | 1983-10-19 | 1985-04-20 | Lilly Co Eli | Foerfarande foer framstaellning av 9-karbamoylfluorenderivat. |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
DD244341A1 (de) | 1985-12-18 | 1987-04-01 | Akad Wissenschaften Ddr | Verfahren zur herstellung neuer 1h-pyrid-2-one |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5221623A (en) | 1986-07-22 | 1993-06-22 | Boyce Thompson Institute For Plant Research, Inc. | Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
JPS63112566A (ja) | 1986-10-28 | 1988-05-17 | Nissan Chem Ind Ltd | ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤 |
US4968707A (en) | 1987-06-10 | 1990-11-06 | Pfizer Inc. | Oxazolidin-2-one derivatives as hypoglycemic agents |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5070012A (en) | 1988-03-30 | 1991-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Monitoring of cells and trans-activating transcription elements |
DE3823991A1 (de) | 1988-07-15 | 1990-02-15 | Basf Ag | Heterocyclisch substituierte (alpha)-aryl-acrylsaeureester und fungizide, die diese verbindungen enthalten |
US5194438A (en) | 1988-07-15 | 1993-03-16 | Basf Aktiengesellschaft | α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods |
DE3922392A1 (de) | 1989-07-07 | 1991-01-17 | Merck Patent Gmbh | Chromanderivate |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
DE3934176A1 (de) | 1989-10-13 | 1991-04-18 | Basf Ag | Cyclische amide |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5399566A (en) | 1990-06-19 | 1995-03-21 | Meiji Seika Kabushiki Kaisha | Pyridine derivatives having angiotensin II antagonism |
US5380721A (en) | 1990-09-10 | 1995-01-10 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
US5283179A (en) | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
CA2095219A1 (en) | 1990-10-31 | 1992-05-01 | Hameed S. Allaudeen | Substituted indolizino[1,2-b]quinolinones |
WO1993020818A1 (en) | 1990-10-31 | 1993-10-28 | Smithkline Beecham Corporation | SUBSTITUTED INDOLIZINO[1,2-b]QUINOLINONES |
US5883255A (en) | 1990-10-31 | 1999-03-16 | Smithkline Beecham Corporation | Substituted indolizino 1,2-b!quinolinones |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
IL100917A0 (en) * | 1991-02-16 | 1992-11-15 | Fisons Plc | Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them |
US5332750A (en) | 1991-09-04 | 1994-07-26 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1,2-dihydro-2-oxopyridines |
DE4129340A1 (de) | 1991-09-04 | 1993-03-11 | Merck Patent Gmbh | 1,2-dihydro-2-oxopyridine |
WO1993006215A1 (en) | 1991-09-17 | 1993-04-01 | The Salk Institute For Biological Studies | Receptor of the thyroid/steroid hormone receptor superfamily |
DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
US5504070A (en) | 1991-12-05 | 1996-04-02 | Berlex Laboratories, Inc. | Inhibitors of the conversion of big endothelin to endothelin |
EP0551572B1 (en) | 1991-12-10 | 1998-12-30 | Bristol-Myers Squibb Company | Tibial resector guide |
DE4141187A1 (de) | 1991-12-13 | 1993-06-17 | Bayer Ag | Verfahren zur herstellung von substituierten pyrazolinen |
US5378720A (en) | 1991-12-19 | 1995-01-03 | Sterling Winthrop Inc. | Saccharin derivative proteolytic enzyme inhibitors |
AU668694B2 (en) | 1991-12-19 | 1996-05-16 | Sanofi-Synthelabo | Saccharin derivative proteolytic enzyme inhibitors |
DK0548680T3 (da) | 1991-12-26 | 1998-09-23 | Mitsubishi Chem Corp | Beta-oxo-beta-benzenpropanthioamidderivater |
WO1993016698A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
DE4206045A1 (de) | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl substituierte pyridone |
JPH07508039A (ja) | 1992-05-20 | 1995-09-07 | メルク エンド カンパニー インコーポレーテッド | 4−アザステロイドのエステル誘導体 |
AU668180B2 (en) | 1992-05-20 | 1996-04-26 | Merck & Co., Inc. | 17-ethers and thioethers of 4-aza-steroids |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9213694D0 (en) | 1992-06-27 | 1992-08-12 | Keynes Roger J | Improvements in or relating to neuroregeneration |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
DE4319041A1 (de) * | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
DE4319040A1 (de) | 1992-10-23 | 1994-04-28 | Bayer Ag | Alkoxymethylsubstituierte Pyridonbiphenyle |
DE4309552A1 (de) | 1993-03-24 | 1994-09-29 | Bayer Ag | Substituierte Stickstoff-Heterocyclen |
US5814645A (en) | 1993-03-24 | 1998-09-29 | Bayer Aktiengesellschaft | Arylor hetaryl substituted nitrogen heterocycles and their use as pesticides |
DE4313747A1 (de) | 1993-04-27 | 1994-11-03 | Bayer Ag | Verfahren zur Herstellung von substituierten Biphenyltetrazolen |
DE4316077A1 (de) * | 1993-05-13 | 1994-11-17 | Bayer Ag | Substituierte Mono- und Bihydridylmethylpyridone |
AP9400651A0 (en) | 1993-07-15 | 1995-12-30 | Pfizer | Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists. |
WO1995003803A1 (en) | 1993-08-03 | 1995-02-09 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
US5514716A (en) | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
DE4407488A1 (de) | 1994-03-07 | 1995-09-14 | Bayer Ag | Verwendung von Biphenyl- und Pyridylmethylpyridonen |
AU684352B2 (en) | 1994-04-08 | 1997-12-11 | Sumitomo Chemical Company, Limited | Ether compound, use thereof, and intermediate for producing the compound |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
DE4414648A1 (de) | 1994-04-27 | 1995-11-02 | Merck Patent Gmbh | Verfahren zur Umsetzung von substituierten Pyrid-2-onen mit Arylalkylhalogeniden |
US5598269A (en) | 1994-05-12 | 1997-01-28 | Children's Hospital Medical Center | Laser guided alignment apparatus for medical procedures |
WO1996003378A1 (fr) | 1994-07-26 | 1996-02-08 | Sankyo Company, Limited | Derives d'amide n-phenyle et d'uree |
JP3466765B2 (ja) | 1994-07-27 | 2003-11-17 | キッコーマン株式会社 | ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体dna、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法 |
US5744482A (en) | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
AU3972195A (en) | 1994-10-12 | 1996-05-06 | Research & Diagnostics Systems, Inc. | Reticulocyte assay control |
US5659042A (en) | 1994-10-25 | 1997-08-19 | Allergan | Method for preparing esters of halonicotinic acids |
US5607967A (en) | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
US5955108A (en) | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
US5514825A (en) | 1994-12-29 | 1996-05-07 | Allergan, Inc. | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5599967A (en) | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
US5618931A (en) | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
EP0800517A1 (en) | 1994-12-29 | 1997-10-15 | Allergan | Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5648514A (en) | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5543534A (en) | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5618943A (en) | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
US5869428A (en) | 1995-03-13 | 1999-02-09 | Ishihara Sangyo Kaisha Ltd. | Pyridonesulfonylurea compounds, process for their production and herbicides containing them |
US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
DE19518739A1 (de) | 1995-05-22 | 1996-11-28 | Basf Ag | N-Aminopyridonderivate |
JPH08325248A (ja) | 1995-05-26 | 1996-12-10 | Chugoku Kayaku Kk | テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法 |
US5612363A (en) | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
WO1996040256A1 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone |
ATE216261T1 (de) | 1995-06-07 | 2002-05-15 | Searle & Co | Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist |
CZ297975B6 (cs) | 1995-06-07 | 2007-05-09 | G. D. Searle & Co. | Farmaceutická kombinace antagonisty receptoru proangiotensin II a epoxymexrenonu pro lécení kardiovaskulárních poruch |
WO1996041633A1 (en) | 1995-06-08 | 1996-12-27 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
AU5966096A (en) | 1995-06-09 | 1997-01-09 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
US5849587A (en) | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
DE19527568A1 (de) | 1995-07-28 | 1997-01-30 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
EP0851767A1 (en) | 1995-09-21 | 1998-07-08 | Quadrant Healthcare (UK) Limited | Transcytosis vehicles and enhancers for drug delivery |
US5888830A (en) | 1995-09-22 | 1999-03-30 | Berlex Laboratories, Inc. | Apparatus and process for multiple chemical reactions |
KR19990063660A (ko) | 1995-09-22 | 1999-07-26 | 벌렉스 래보라토리즈, 인크. | 다중 화학 반응을 위한 장치 및 방법 |
JP2002500618A (ja) | 1995-10-31 | 2002-01-08 | イーライ・リリー・アンド・カンパニー | 抗血栓性ジアミン |
US5994375A (en) | 1996-02-12 | 1999-11-30 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
AU4837996A (en) | 1996-02-29 | 1997-09-16 | Delta Biotechnology Limited | High purity albumin production process |
US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
CA2249652A1 (en) | 1996-03-15 | 1997-10-02 | Eli Lilly And Company | Method of treating common cold or allergic rhinitis |
US5869497A (en) | 1996-03-15 | 1999-02-09 | Eli Lilly And Company | Method of treating or ameliorating the symptoms of common cold or allergic rhinitis |
EP0802192A1 (de) | 1996-04-17 | 1997-10-22 | Bayer Ag | Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung |
DE19619950A1 (de) | 1996-04-17 | 1997-10-23 | Bayer Ag | Heterocyclisch-substituierte Phenylglycinolamide |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5747542A (en) | 1996-06-21 | 1998-05-05 | Allergan | Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
EP0915825B1 (en) | 1996-06-21 | 2004-05-06 | Allergan, Inc. | Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5808124A (en) | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US5723666A (en) | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5618503A (en) | 1996-06-28 | 1997-04-08 | Chemical Research & Licensing Company | Antimony pentafluoride |
DE19627421A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Verwendung von substituierten Biphenylen |
US5753635A (en) | 1996-08-16 | 1998-05-19 | Berlex Laboratories, Inc. | Purine derivatives and their use as anti-coagulants |
US5693641A (en) | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
AU4074897A (en) | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
US5955604A (en) | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
EP0933996B1 (de) | 1996-10-17 | 2001-08-16 | Basf Aktiengesellschaft | Verfahren zur bekämpfung von schadpilzen in kulturpflanzen |
ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
EP1082958A3 (en) | 1996-11-15 | 2002-12-11 | Eli Lilly And Company | 5-HT1F agonists in chronic pain |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
PL334840A1 (en) | 1997-01-24 | 2000-03-27 | Univ California | Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation |
US5855654A (en) | 1997-01-30 | 1999-01-05 | Rohm And Haas Company | Pyridazinones as marine antifouling agents |
US5760276A (en) | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
AU7274098A (en) | 1997-04-30 | 1998-11-24 | Eli Lilly And Company | Antithrombotic agents |
EP1027051B1 (en) | 1997-04-30 | 2005-01-05 | Eli Lilly And Company | Antithrombotic agents |
JP3771672B2 (ja) | 1997-05-27 | 2006-04-26 | 曙ブレーキ工業株式会社 | ブレーキペダル操作検出装置 |
DE19729061A1 (de) | 1997-07-08 | 1999-01-14 | Agfa Gevaert Ag | Farbfotografisches Aufzeichnungsmaterial |
US6380201B1 (en) | 1997-08-05 | 2002-04-30 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
GB9723078D0 (en) | 1997-10-31 | 1998-01-07 | Cerebrus Ltd | Chemical compounds |
US6054470A (en) | 1997-12-18 | 2000-04-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Src family SH2 domain inhibitors |
US6156784A (en) | 1997-12-18 | 2000-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as phosphotyrosine mimics |
AU2610299A (en) | 1998-02-05 | 1999-08-23 | Novo Nordisk A/S | Hydrazone derivatives |
WO1999052893A1 (en) | 1998-04-08 | 1999-10-21 | Novartis Ag | N-pyridonyl herbicides |
KR20010087128A (ko) | 1998-04-27 | 2001-09-15 | 피에르 베르농 | 3-(아미노- 또는 아미노알킬)피리디논 유도체 및그의hiv 관련 질병의 치료 용도 |
DE19826671A1 (de) | 1998-06-16 | 1999-12-23 | Hoechst Schering Agrevo Gmbh | 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
WO2000017334A2 (en) | 1998-09-23 | 2000-03-30 | Ludmila Solomin | Analysis of ligand activated nuclear receptors i(in vivo) |
JP2002528721A (ja) | 1998-10-23 | 2002-09-03 | グラクソ グループ リミテッド | 核内受容体のリガンド用のアッセイ |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
EP1006108A1 (en) | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
EP1006112A1 (en) | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
US6294503B1 (en) | 1998-12-03 | 2001-09-25 | Ishihara Sangyo Kaisha, Ltd. | Fused heterocycle compounds, process for their preparation, and herbicidal compositions containing them |
AU2389100A (en) | 1998-12-23 | 2000-07-12 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
AU2409600A (en) | 1999-01-07 | 2000-07-24 | Tularik Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
US6071955A (en) | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
US6316503B1 (en) * | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
DE60013417T2 (de) | 1999-03-26 | 2005-09-15 | City Of Hope, Duarte | Verfahren zum screenen von fxr-rezeptormodulatoren |
AU4641400A (en) | 1999-06-02 | 2000-12-18 | Ishihara Sangyo Kaisha Ltd. | Fused tricyclic compounds, process for their preparation, and herbicidal compositions containing them |
AR024576A1 (es) | 1999-06-18 | 2002-10-16 | Univ Washington | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp |
JP2004500332A (ja) | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Hdlコレステロール値を上昇させる組成物および方法 |
AU1291901A (en) | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
IT1317904B1 (it) | 1999-09-11 | 2003-07-15 | Glaxo Group Ltd | Formulazione farmaceutica di propionato di fluticasone. |
EP1242080A4 (en) | 1999-09-27 | 2003-01-22 | Univ Georgetown | INHIBITORS OF DOPAMINE TRANSPORT AND THEIR USE |
US6444471B1 (en) | 1999-10-18 | 2002-09-03 | Research & Diagnostic Systems, Inc. | Reticulocyte containing complete blood control |
ES2234694T3 (es) | 1999-11-23 | 2005-07-01 | Glaxo Group Limited | Formulaciones farmaceuticas de salmeterol. |
CN1196682C (zh) | 1999-12-06 | 2005-04-13 | 霍夫曼-拉罗奇有限公司 | 4-吡啶基-n-酰基-l-苯丙氨酸 |
US20020160067A1 (en) | 2001-04-25 | 2002-10-31 | Oncology Science Corporation | Therapeutic preparation and method for producing a therapeutic preparation using coffee beans as a substrate |
US20030032632A1 (en) | 1999-12-24 | 2003-02-13 | Crispps Leslie Alan | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
WO2001060818A1 (en) | 2000-02-14 | 2001-08-23 | Tularik Inc. | Lxr modulators |
US6378919B1 (en) | 2000-04-04 | 2002-04-30 | International Truck Intellectual Property Company, L.L.C. | Cylindrical lock with slam latch and auxiliary cable release |
JP2001302637A (ja) | 2000-04-20 | 2001-10-31 | Nippon Kayaku Co Ltd | 感熱転写記録用色素及び感熱転写シート |
US20020048572A1 (en) | 2000-05-03 | 2002-04-25 | Bei Shan | Treatment of hypertriglyceridemia and other conditions using LXR modulators |
WO2001096308A1 (fr) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | Composes 1,2-dihydropyridine, leur procede de preparation et leur utilisation |
US6252090B1 (en) | 2000-08-29 | 2001-06-26 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6313107B1 (en) | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
US6303785B1 (en) | 2000-08-29 | 2001-10-16 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6380256B1 (en) | 2000-08-29 | 2002-04-30 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6291677B1 (en) | 2000-08-29 | 2001-09-18 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6369225B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6387951B1 (en) | 2000-08-29 | 2002-05-14 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6369261B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
ATE315558T1 (de) | 2000-08-29 | 2006-02-15 | Allergan Inc | Verbindungen mit cytochrom p450ra1 hemmenden aktivität |
UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
PL366311A1 (en) | 2000-12-11 | 2005-01-24 | Tularik Inc. | Cxcr3 antagonists |
US8176425B2 (en) | 2001-02-02 | 2012-05-08 | Ensequence, Inc. | Animated screen object for annotation and selection of video sequences |
ES2299567T3 (es) | 2001-05-05 | 2008-06-01 | Smithkline Beecham Plc | N-aroilaminas ciclicas. |
WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
JP4399256B2 (ja) | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
AU2002351412B2 (en) * | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
WO2004103974A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | 置換2-オキソキノリン化合物およびその医薬用途 |
CN1289803C (zh) | 2004-05-16 | 2006-12-13 | 王永钦 | 汽车冷却风扇驱动机构总成 |
-
2002
- 2002-12-20 AU AU2002351412A patent/AU2002351412B2/en not_active Ceased
- 2002-12-20 JP JP2003559988A patent/JP5082033B2/ja not_active Expired - Lifetime
- 2002-12-20 WO PCT/US2002/041306 patent/WO2003059884A1/en active Application Filing
- 2002-12-20 CA CA002469435A patent/CA2469435A1/en not_active Abandoned
- 2002-12-20 ES ES02787071T patent/ES2421511T3/es not_active Expired - Lifetime
- 2002-12-20 EP EP02787071.6A patent/EP1465869B1/en not_active Expired - Lifetime
- 2002-12-20 US US10/327,813 patent/US7998986B2/en active Active
-
2010
- 2010-09-22 JP JP2010212875A patent/JP2010280732A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010280732A (ja) * | 2001-12-21 | 2010-12-16 | X-Ceptor Therapeutics Inc | Lxrのモジュレーター |
Also Published As
Publication number | Publication date |
---|---|
US7998986B2 (en) | 2011-08-16 |
AU2002351412A1 (en) | 2003-07-30 |
JP2005536450A (ja) | 2005-12-02 |
WO2003059884A1 (en) | 2003-07-24 |
ES2421511T3 (es) | 2013-09-03 |
US20030181420A1 (en) | 2003-09-25 |
EP1465869A4 (en) | 2005-12-28 |
EP1465869A1 (en) | 2004-10-13 |
CA2469435A1 (en) | 2003-07-24 |
EP1465869B1 (en) | 2013-05-15 |
AU2002351412B2 (en) | 2010-05-20 |
JP2010280732A (ja) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5082033B2 (ja) | Lxrのモジュレーター | |
EP1572660B1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
JP5017607B2 (ja) | 核レセプターのモジュレーター | |
ES2233700T3 (es) | Derivados de aminopropoxiarilo sustituidos utiles como agonistas para lxr. | |
US6492425B1 (en) | Inhibitors of transcription factor-NF-κB | |
CN101772487B (zh) | 甲状腺类化合物 | |
CN101432265B (zh) | 11-β-羟类固醇脱氢酶1的抑制剂 | |
EP1521746B1 (en) | Quinazolinone modulators of nuclear receptors | |
KR101363278B1 (ko) | 이미다졸계 lxr 변조제 | |
US20090298808A1 (en) | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same | |
AU2010254082B2 (en) | LXR modulators | |
EP1407774A1 (en) | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds | |
CZ403192A3 (en) | Substituted bicyclic bis-aryl derivatives, process of their preparation and their use in pharmaceutical compositions | |
KR20060052867A (ko) | 약제로서의 아제핀 유도체 | |
JP2003504644A (ja) | Scapアンタゴニストである治療剤のスクリーニング | |
WO2010006496A1 (zh) | 用作雌激素相关受体调节剂的化合物及其应用 | |
ZA200007448B (en) | Inhibitors of transcription factor NF-kB. | |
TWI762634B (zh) | 胺基-芳基-苯甲醯胺化合物及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051219 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060323 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100112 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100310 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110817 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120329 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120423 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120727 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5082033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |